FDA publishes complete response letter for Disc Medicine's (IRON) NDA for bitopertin; have completed review of this application, as amended, and have determined that we cannot approve this application in its present form

The FDA's decision to publish a complete response letter for Disc Medicine's NDA indicates significant regulatory hurdles, suggesting that the current formulation of bitopertin is not approvable as is.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Fed's Goolsbee (2027 voter) says we are still seeing pretty high services inflation; hopes we've seen peak impact of tariffs; the job market has been steady, only modest cooling

Senate Democrats demand answers from Treasury Secretary Bessent and Secretary of State Rubio on the US lifting spyware sanctions, according to a letter

FDA publishes complete response letter for Disc Medicine's (IRON) NDA for bitopertin; have completed review of this application, as amended, and have determined that we cannot approve this application in its present form

US nuclear regulator issues permit for X-energy high assay low enriched uranium fuel (Haleu) plant for planned high-tech reactors

Pennsylvania jury finds Johnson & Johnson (JNJ) liable for woman's ovarian cancer

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could negatively impact Disc Medicine's stock performance and may reflect broader caution regarding new drug approvals, potentially affecting investor sentiment in the biotech sector. Investors should monitor for any subsequent announcements that could address the FDA's concerns.

Related headlines

The whole workspace, free to try.

Try it free